Pfizer and Biontech SE have reached an agreement with the European Commission to supply 200 million doses of their mRNA-based COVID-19 vaccine candidate.
More than 1,800 attendees already registered for the Global Bioeconomy Summit 2020. The conference takes place virtually from November 16 to 20.
Interim data on BioNtech’s/Pfizer’s COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.
Swiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedica’s experimental kidney drug ANG-3777.
Japanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia.
Lead investor Novo Growth has led a €22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.
HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
Boehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.
British SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals.
Swedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region